LATEST TRIALS

  • Skin Cancer
    A Phase 2, Open-Label, Single Arm study to evaluate the safety and efficacy of Pembrolizumab in participants with recurrent or mestastatic cutanous squamous cell carcinoma
  • Prostate Cancer
    Safety and pharmacokinetics of ODM-208 in patients with metastatic castration-resistant prostate cancer
  • Colorectal Cancer
    Protocol for treatment under Hospital Exemption:T cell receptor based therapy of metastatic colorectal cancer with mRNA-engineered T cells targeting transforming growth factor beta receptor type II (TGFβII)

NORDIC COOPERATION

Norway Norway Sweden Finland Aarhus Herlev Copenhagen